Biomarkers of Acrylamide, Glycidol, POPs, PFAS and Disease Outcomes and OMICs Signatures

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05930626

Enrollment

9254

Registered

2023-07-05

Start date

1997-01-01

Completion date

2008-12-31

Last updated

2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Cardiovascular Diseases, Disease, Environmental Exposure

Brief summary

The aim of the project is to assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with persistent organic pollutants (POPs) and per- and polyflouroalkyl substances (PFAS) using a prospective cohort study utilizing and integrating various 'OMICs' technologies.

Interventions

OTHERBiomarkers of acrylamide, glycidol, POPs, PFAS

These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* 60YO: Men and women of 60 years old residing in Stockholm * SMC-C: Women residing in Uppsala

Exclusion criteria

* Subjects will be excluded if they had the outcome under investigation at baseline

Design outcomes

Primary

Measure	Time frame	Description
Cardiovascular disease	From baseline beginning in 2003 through 2017	Using International Classification of Diseases (ICD) codes to assess cardiovascular disease (CVD) incidence (myocardial infarction and stroke, ICD10: I21 and I63)
Cancer	From baseline (2003 for SMC-C and 1997 for 60YO) until the latest available follow-up, currently 2021	Using ICD codes to assess cancer (such as ICD-10: C18, C20, C50, C54)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026